Our executive team at Peptone is expanding

Dr Kamil Tamiola, the CEO and founder of Peptone stands next to prototypical HDX-MS system for disordered proteins of Peptone’s proprietary Oppenheimer platform. Photo credit: Elia Gamba, Peptone’s Photo Archive.

I have some exciting news to share! Peptone has appointed some amazing people to Peptone's Executive Management Team and Board of Directors. Patrik Foerch, PhD, is now the Chief Scientific Officer. David Lowe, PhD, is the new Senior Vice President of Protein Therapeutics. Benjamin Owens, PhD, has transitioned to Chief Business Officer and will join Peptone’s Board of Directors as Executive Director. Andrew Allen, MD PhD, co-founder, President and CEO of Gritstone Bio, has been appointed Board Chair.

Patrik has been active in drug discovery for over 20 years and will lead our cross-functional teams. David has been working in the biologics discovery field for over 25 years and has led teams at AstraZeneca and Evox Therapeutics. Ben has a lot of experience in the biopharmaceutical industry and has been with us since 2021. He will spearhead our business development efforts.

I am genuinely thrilled to have these amazing people on my team and can't wait to see what we'll accomplish together!

You can read more about our team on our websiteany/. The original press release can be found here.